Primary Central Nervous System Lymphoma Clinical Trials

22 recruiting

Primary Central Nervous System Lymphoma Trials at a Glance

34 actively recruiting trials for primary central nervous system lymphoma are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Beijing, New York, and Boston. Lead sponsors running primary central nervous system lymphoma studies include Dana-Farber Cancer Institute, Navy General Hospital, Beijing, and Second Affiliated Hospital, School of Medicine, Zhejiang University.

Browse primary central nervous system lymphoma trials by phase

Treatments under study

About Primary Central Nervous System Lymphoma Clinical Trials

Looking for clinical trials for Primary Central Nervous System Lymphoma? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Central Nervous System Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Central Nervous System Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 3

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled8 locationsNCT07104032
Recruiting
Phase 1

Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma

Relapsed/Refractory Primary Central Nervous System LymphomaRelapsed/Refractory Central Nervous System LymphomaRelapsed/Refractory Secondary Central Nervous System Lymphoma
Beijing Boren Hospital30 enrolled1 locationNCT07555561
Recruiting
Phase 1Phase 2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 2

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 1

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Primary Central Nervous System Lymphoma
National Cancer Institute (NCI)93 enrolled1 locationNCT02203526
Recruiting
Phase 2

A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 2

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1Phase 2

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

LymphomaPrimary Central Nervous System Lymphoma
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06475235
Recruiting
Phase 1

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Primary Central Nervous System Lymphoma (PCNSL)
Ting YANG20 enrolled1 locationNCT07188077
Recruiting
Phase 1

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
City of Hope Medical Center20 enrolled1 locationNCT06922604
Recruiting
Phase 1

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co. Ltd32 enrolled2 locationsNCT07198087
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 1Phase 2

A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT06556199
Recruiting
Not Applicable

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

Primary Central Nervous System Lymphoma (PCNSL)
The First Affiliated Hospital of Soochow University40 enrolled1 locationNCT07074470
Recruiting
Phase 2

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Primary Central Nervous System LymphomaNon-Hodgkin Lymphoma of Extranodal Site
Lakshmi Nayak, MD25 enrolled2 locationsNCT04906096
Recruiting
Phase 2

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Primary Central Nervous System Lymphoma
Providence Health & Services28 enrolled7 locationsNCT06175000
Recruiting
Phase 2

High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma (PCNSL)
Sichuan University34 enrolled1 locationNCT07014943